RAPIDO: Condolences

Bruna B Vailati^{1

2

3}, Carlos Cerdán-Santacruz⁴, Guilherme P São Julião^{1

2

3}, Leonardo Ervolino Corbi^{1

2

3}, Rodrigo O Perez^{1

2

3}

Affiliations

¹ Angelita and Joaquim Gama Institute, São Paulo, Brazil.
² Department of Surgical Oncology, Hospital Beneficencia Portuguesa, São Paulo, Brazil.
³ Hospital Alemão Oswaldo Cruz, São Paulo, Brazil.
⁴ Hospital de la Princesa, Madrid, Spain.

Bruna B Vailati et al. Dis Colon Rectum. 2024.

. 2024 Mar 1;67(3):e206.

doi: 10.1097/DCR.0000000000003179. Epub 2023 Dec 5.

Bruna B Vailati^{1

2

3}, Carlos Cerdán-Santacruz⁴, Guilherme P São Julião^{1

2

3}, Leonardo Ervolino Corbi^{1

2

3}, Rodrigo O Perez^{1

2

3}

¹ Angelita and Joaquim Gama Institute, São Paulo, Brazil.
² Department of Surgical Oncology, Hospital Beneficencia Portuguesa, São Paulo, Brazil.
³ Hospital Alemão Oswaldo Cruz, São Paulo, Brazil.
⁴ Hospital de la Princesa, Madrid, Spain.

No abstract available

References

1. Bettoni F, Masotti C, Corrêa BR, et al. The effects of neoadjuvant chemoradiation in locally advanced rectal cancer-the impact in intratumoral heterogeneity. Front Oncol. 2019;9:974.
1. Perez RO, Habr-Gama A, São Julião GP, et al. Optimal timing for assessment of tumor response to neoadjuvant chemoradiation in patients with rectal cancer: do all patients benefit from waiting longer than 6 weeks? Int J Radiat Oncol Biol Phys. 2012;84:1159–1165.
1. Bahadoer RR, Dijkstra EA, van Etten B, et al.; RAPIDO collaborative investigators. Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22:29–42.
1. Garcia-Aguilar J, Patil S, Gollub MJ, et al. Organ preservation in patients with rectal adenocarcinoma treated with total neoadjuvant therapy. J Clin Oncol. 2022;40:2546–2556.
1. Fokas E, Allgäuer M, Polat B, et al.; German Rectal Cancer Study Group. Randomized phase II trial of chemoradiotherapy plus induction or consolidation chemotherapy as total neoadjuvant therapy for locally advanced rectal cancer: CAO/ARO/AIO-12. J Clin Oncol. 2019;37:3212–3222.